8. bibliography - shodhgangashodhganga.inflibnet.ac.in/bitstream/10603/25882/14/part... · 2018. 7....
TRANSCRIPT
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
278
8. BIBLIOGRAPHY
Alan, D.B., Anne, M.E., Terry, M.H., Deborah, L.J., Andrew, M.M., Gordon, G.W.,
2002. Pyrrolidine-5,5-trans-lactams as Novel Mechanism-BasedInhibitors of
Human Cytomegalovirus Protease. Part 3:Potency and Plasma Stability
Bioorganic & Medicinal Chemistry Letters 12: 1719–1722.
Andrew, T., Turrisi, III., 1997. Combined Modality Therapy for Lung Cancer: Principles
to Practice. Oncologist (2): 192-195.
Ansede, J.H., Thakker, D.R., 2004. High –throughput screening for stability and
inhibitory activity of compound towards cytochrome P450- mediated
metabolism . J Pharm Sci 93(2): 293.
Anuj, K., Sangram, K.S., Kumud, P., Prithi, P.S.K., Ajit, S., Naveen P., 2011. Review on
solubility enhancement techniques for hydrophobic drugs, International journal
of comprehensive pharmacy 3(03).
Arutsson, P., Palm, K., Luthaman, K., 1996. Caco-2 monolayers in experimental and
theoretical prediction of drug transport. Adv Drug Del Rev 22: 67-84.
Aungst B. J., 1993. Novel formulation strategies for improving oral bioavailability of
drug with poor membrane permeation or presystemic metabolism. J Pharm Sci
82: 979–987.
Austel, V., 1989. The medicinal chemist's approach, in Modern Drug Research, Paths to
Better and Safer Drugs. Martin, Y.C., Kutter, E., Austel, V., Eds, Marcel
Dekker, Inc., New York, 243-307.
Avdeef, A., 2001. Physicochemical profiling (solubility, permeability and charge state.
Curr Topics Med Chem 1: 277-351.
Avery, M.J., 2003. Quantitative characterization of differential ion suppression on liquid
chromatography/atmospheric pressure ionization mass spectrometric
bioanalytical methods. Rapid Commun Mass Spectrom 17:197- 201.
Bache, M., Zschornak, P.M., Passin, S., Ke, J., Wichmann, H., Kappler, M., Paschke,
R., Kaluđerović, G.N., Kommera, H., Taubert, H., Vordermark, D., 2011.
Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma
cells under hypoxic conditions, Radiation Oncology 6:111.
Bagnati, R., Fanelli, R., 1991. Determination of 19-nortestosterone, testosterone and
trenbolone by gas chromatography-negative-ion mass spectrometry after
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
279
formation of the pentafluorobenzylcarboxymethoxime-trimethylsilyl
derivatives. J Chromatogr 547: 325-334.
Baker, H.J., Lindsey, J.R., Weisbroth, S.H., 1979. The laboratory Rat, Vol. 1, Biology
and Diseases. Academic Press, New York, 87.
Balani, S.K., Miwa, G.T., Gan, L.S., Wu, J.T., Lee, F.W., 2005. Strategy of utilizing in
vitro and in vivo ADME tools for lead optimization and drug candidate
selection. Curr Top Med Chem 5(11): 1033-8.
Balimane, P.V., Chong, S., 2005. DDT 10(5): 335-343.
Baran, C.Z., Staricza, K.A., Sundberg, K., Sundberg, R., Wallin, A., Jansson, L., Garberg,
P., 2006. Introduction to in vitro estimation of metabolic stability and drug
intraction of new chemical entities in drug discovery and development.
Pharmacol Rep 58(4): 453.
Belanger, B., Couture, J., Caron, S., Bodou, P., Fiet, J., Belanger, A., 1990. Production
and secretion ofC-19 steroids by rat and guinea pig adrenals. Steroids 55(8):
360-365.
Benet, L.Z., 1978. Effect of route of administration and tissue distribution on drug action.
J Pharmacokinet Biopharm 6: 559-585.
Benet, L.Z., Mitchell, J.R., Sheiner, L.B. 1990. Pharmacokinetics : The dynamics of drug
absorption, distribution and elimination. In: The Pharmacological Basis of
Therapeutics, A Goodman Gilman, T.W., Rall, A.S., Nies, and P., Taylor, (eds).
Pergamon Press, Oxford, 1-32.
Benet, L.Z., Sheiner, L.B., 1985. Pharmacokinetics: The dynamics of drug absorption
distribution andelimination. In: The Pharmacological Basis of Therapeutics,
A.G., Gilman, L.S., Goodman, T.W., Ball, F., Mirac, (eds). Macmillan, New
York, 3-34.
Berger, M.R., 1999. Autochthonous tumour models in rats: Is there a relevance for
anticancer drug development. In: Fiebig HH, Burger AM, editors. Relevance of
Tumour Models for Anticancer Drug Development. Contrib Oncol 54: 15–27.
Berk, P.D., Potter, B.J., Stremmel, W., 1987. Role of plasma membrane ligand binding
proteins in the hepatocellular uptake of albumin bound anions. Hepatology 7:
165-176.
http://www.ncbi.nlm.nih.gov/pubmed?term=Balani%20SK%5BAuthor%5D&cauthor=true&cauthor_uid=16181128http://www.ncbi.nlm.nih.gov/pubmed?term=Miwa%20GT%5BAuthor%5D&cauthor=true&cauthor_uid=16181128http://www.ncbi.nlm.nih.gov/pubmed?term=Gan%20LS%5BAuthor%5D&cauthor=true&cauthor_uid=16181128http://www.ncbi.nlm.nih.gov/pubmed?term=Wu%20JT%5BAuthor%5D&cauthor=true&cauthor_uid=16181128http://www.ncbi.nlm.nih.gov/pubmed?term=Lee%20FW%5BAuthor%5D&cauthor=true&cauthor_uid=16181128http://www.ncbi.nlm.nih.gov/pubmed/16181128
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
280
Berman, J., Halm, K., Adkison, K., Shaffer, J., 1997. Simultaneous pharmacokinetic
screening of a mixture of compounds in dog using API/LC/MS/MS for
increased throughput. J Med Chem 40: 827-829.
Bertz, R.J., granneman, G.R., 1997. Use of in vitro and in vivo data to estimate the
likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:
210-258.
Bibby, M.C., 1999. Transplantable tumours in mice—the way forward. In: Burger AM,
editor. Relevance of tumour models for anticancer drug development. Contrib
Oncol 54: 1–13.
Bibby, M.C., 2004. Orthotopic models of cancer for preclinical drug evaluation:
advantages and disadvantages. Eur J Cancer 40: 852–7.
Bickel, M.H., 1975. Binding of chlorpromazine and imipramine to red cells, albumin,
Lipoproteins and other blood components. J Phrm Pharmacol 27: 733.
Bjorge, S., Halelehle, K.L., Homan, R., Rose, S.E., Turluck, D.A., Wright, D.S., 1991.
Evidence for glucuronide conjugation of p-nitrophenol in the CaCO-2 cell
model. Pharm Res 8: 1441-1443.
Bohets, H., Annaert, P., Mannens, G., Van, B.L., Anciaux, K., Verboven, P.,
Meuldermans, W., Lavrijsen, K., 2001. Strategies for absorption screening in
drug discovery and development. Curr Top Med Chem 1(5): 367.
Boik, J., 2001a. Natural compounds in cancer therapy. 1st Ed. Oregon Medical Press,
LLC, USA, 1-2.
Boobis, A., Gundert-Remy, U., Kremers, P., Macheras, P., Pelkonen, O., 2002. In silico
prediction of ADME and pharmacokinetics. Report of an expert meeting
organised by COST B15. Eur J Pharm Sci 17(4-5): 183-93.
Boyle, P., Levin, B., 2008. ―World Cancer Report 2008‖ IARC Nonserial Publication
(2008)
Bressolle, F., Bromet, P.M., Audran, M., 1996. Validation of liquid chromatographic and
gas chromatographic methods. Applications to pharmacokinetics. J Chromatogr
B 686(1): 3-10.
http://www.ncbi.nlm.nih.gov/pubmed?term=Boobis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=12453607http://www.ncbi.nlm.nih.gov/pubmed?term=Gundert-Remy%20U%5BAuthor%5D&cauthor=true&cauthor_uid=12453607http://www.ncbi.nlm.nih.gov/pubmed?term=Kremers%20P%5BAuthor%5D&cauthor=true&cauthor_uid=12453607http://www.ncbi.nlm.nih.gov/pubmed?term=Macheras%20P%5BAuthor%5D&cauthor=true&cauthor_uid=12453607http://www.ncbi.nlm.nih.gov/pubmed?term=Pelkonen%20O%5BAuthor%5D&cauthor=true&cauthor_uid=12453607http://www.ncbi.nlm.nih.gov/pubmed/12453607
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
281
Brodie. B.B., 1964. Physicochemical factors in drug absorption. In: Absorption and
Distribution of Drugs, TB Binns (ed). Williams and Wilkin, Baltimore,
Maryland, 16-48.
Bullock, P., Larsen, D., Press, R., Wehrman, T., Martin, D.E., 2008. The absorption,
distribution, metabolism and elimination of bevirimat in rats. Biopharm Drug
Dispos 29(7): 396-405.
Burger, A.M., 1999. Relevance of tumour models for anticancer drug development.
Contrib Oncol 54: 1–13.
Burton, P.S., Conradi, R.A., Gi, N.F.H., Hilgers, A.R., Borchardt, R.T., 1996. How
structural features influence the biomembrane permeability of peptides. J Pharm
Sci 85: 1336-1340.
Buters, J.T., Korzekwa, K.R., Kunze, K.L., Omata, Y., Hardwick, J.P., Gonzalez, F.J.,
1994. cDNA-directed expression of human cytochrome P450 CYP3A4 using
baculovirus. Drug Metab Dispos 22(5): 688-92.
Caldwell, G.W., Ritchie, D.M., Masucci, J.A., Hageman, W., Yan, Z., 2001. The new
pre-preclinical paradigm: compound optimization in early and late phase drug
discovery. Curr Top Med Chem (5): 353-66.
Caldwell, J., 1988. Xenobiotic metabolism—An introduction. In: Intermediary
Xenobiotic Metabolism, DH Hutson, J Caldwell, and GA Paulson (eds). Taylor
& Francis, London, 3-12.
Camenisch G., Alsenz, J., van de Waterbeemd, H., Folkers, G., 1998. Estimation of
permeability by diffusion through Caco-2 cell monolayers using the drugs´
liphophilicity and molecular weight. Eur J Pharm Sci 6: 313-319.
Campling, B., Pym, J., Baker, H., 1991. Chemosensitivity testing of small cell lung
cancer using the MTT assay. Br J Cancer 63: 75–83
Carmichael, J., DeGraff, W.G., Gazdar, A.F., Minna, J.D., Mitchell, J.B., 1987.
―Evaluation of a tetrazolium-based semiautomated colorimetric assay:
assessment of chemosensitivity testing‖. Cancer Res 47: 936-942.
Carmichael, J.W.G., DeGraff, A.F., Gazdar, J.D., Minna J.B.M. 1987. Evaluation of a
tetrazolium-based semiautomated colorimetric assay: assessment of
radiosensitivity. Cancer Res 47: 943-946.
Causon, R., 1997. Validation of chromatographic methods in biomedical analysis.
http://www.ncbi.nlm.nih.gov/pubmed?term=Caldwell%20GW%5BAuthor%5D&cauthor=true&cauthor_uid=11899102http://www.ncbi.nlm.nih.gov/pubmed?term=Ritchie%20DM%5BAuthor%5D&cauthor=true&cauthor_uid=11899102http://www.ncbi.nlm.nih.gov/pubmed?term=Masucci%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=11899102http://www.ncbi.nlm.nih.gov/pubmed?term=Hageman%20W%5BAuthor%5D&cauthor=true&cauthor_uid=11899102http://www.ncbi.nlm.nih.gov/pubmed?term=Yan%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=11899102http://www.ncbi.nlm.nih.gov/pubmed/11899102
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
282
Viewpoint and discussion. J Chromatogr B 689: 175-180.
Cayen, M.N., 1995. Considerations in the design of toxicokinetic programs. Tox Path 23:
148-157.
CDER Drug Development and Drug Interactions website.
http://www.fda.gov/cder/drug/drugInteractions/default.htm
Charles, G.S., 1992. The process of new drug delivery and development. CRC Press, Inc.
Boca Raton, Florida, USA.
Chatterjee, P., Kouzi, S. A., Pezzuto, J. M., Hamann, M. T., 2000. Biotransformation of
the antimelanoma agent betulinic acid by Bacillus megaterium ATCC 13368,
Appl Environ Microbiol 66: 3850-3855.
Chatterjee, P., Pezzuto, J.M., Kouzi, S.A., 1999. Glucosidation of betulinic acid by
Cunninghamella species. J Nat Prod 62: 761–763.
Chaturvedi, P.R., decker, C.J., Odinecs, A., 2001. Prediction of pharmacokinetics
properties using experimental approaches during early drug discovery. Curr
Opin Chem Biol 5(4): 425.
Cheeke, P.R., Digestive Physiology in Rabbit Feeding and Nutrition. Orlando, FL:
Academic Press. 20: 1987.
Chen, J., Korfmacher, W.A., Hsieh, Y., 2005. Chiral liquid chromatography-tendem
mass spectrometric methods for stereoisomeric pharmaceutical determinations.
J Chromatogr B 820: 1-8.
Chen, W.D., Liang. Y., Xie, L., Lu, T., Liu, X.D., Wang, G.J., 2007. Biol Pharm Bull 30:
1–5. Chen, W.D., Liang, Y., Li, H., Xiong, Y., Liu, X.D., Wang, G.J., Xie, L.,
2006. J Pharm Biomed Anal 41: 256–260.
Cheng, X., Shin, Y.G., Levine, B.S., Smith, A.C., Tomaszewski, J.E., Van-Breemen,
R.B., 2003. Quantitative analysis of betulinic acid in mouse, rat and dog plasma
using electrospray liquid chromatography/mass spectrometry. Rapid Commun
Mass Spectrom 17(18): 2089-92.
Chintharlapalli, S., Papineni, S., Lei, P., Pathi, S., Safe, S., 2011. Betulinic Acid Inhibits
Colon Cancer Cell And Tumor Growth And Induces Proteasomedependent
And - Independent Downregulation Of Specificity Proteins (Sp)
http://www.fda.gov/cder/drug/drugInteractions/default.htmhttp://www.ncbi.nlm.nih.gov/pubmed?term=Cheng%20X%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=Shin%20YG%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=Levine%20BS%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=Smith%20AC%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=Tomaszewski%20JE%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=van%20Breemen%20RB%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=van%20Breemen%20RB%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=Cheng%202003%20Quantitative%20analysis%20of%20betulinic%20acid%20in%20mousehttp://www.ncbi.nlm.nih.gov/pubmed?term=Cheng%202003%20Quantitative%20analysis%20of%20betulinic%20acid%20in%20mouse
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
283
Transcription Factors, BMC Cancer 11: 371.
Chu, L., Nomeir, A.A., 2006. Utility of mass spectrometry for in vitro ADME assays.
Curr Drug Metab 7(5): 467.
Cichewicz, R.H., Kouzi, S.A., 2004. Chemistry, biology activity, and chemotherapeutic
potential of betulinic acid for the prevention and treatment of cancer and HIV
infection. Med Res Rev 24: 90-114.
Clark, A.M., Hufford, C.D., 1991. Use of microorganisms for the study of drug
metabolism: An update. Med Res Rev 11: 437–501.
Clarke, N.J., Rindgen, D., Korfmacher, W.A., Cox, K.A., 2001. Systematic LC-MS
metabolite identification in drug discovery. Anal Chern 73: 430.
Cole, S.P., 1986. Rapid chemosensitivity testing of human lung tumor cells using the
MTT assay. Cancer Chemother Pharmacol 17(3): 259–263.
Copechot, C., Young, J., Calve, M., Wehrey, C., Veltz, I.N., Touyer, G., Mouren, M.,
Prasad, V.V.K., Banner, C., Sjovali, J., Baulieu, E.E., Robel P., 1993.
Neurosteroid3α: -hydroxy-5a-pregnan-20-one and its precursors in the brain,
plasma, and steroidogenic glands of male and female rats. Endocrinology 133:
1003-1009.
Covey, T.R., Lee, E.D., Henion, J.D., 1986. High-speed liquid chromatography/tandem
mass spectrometry for the determination of drugs in biological samples. Anal
Chern 58: 2453-2460.
Cragg, G.M., Newman, D.J., 2005. Plants as a source of anti-cancer agents. J
Ethnopharmacol 100(1-2): 72-79.
Crespi, C.L., Gonzalez, F.J., Steimel, D.T., Turner, T.R., Gelboin, H.V., Penman, B.W.,
Langenbach, R., 1991. A metabolically competent human cell line expressing
five cDNAs encoding procarcinogen-activating enzymes: aplication to
mutagenicity testing. Chem Res Toxicol 4: 566-572.
Croley, T.R., Hughes, R.J., Koenig, B.G., Metcalf, C.D., March, R.E., 2000. Mass
spectrometry applied to the analysis of estrogens in the environment. Rapid
Commun Mass Spectrom 14: 1087-1093.
Dadgar, D., Burnett, P.E., 1995. Issues in evaluation of bioanalyticaJ method selectivity
and drug stability. Pharm Biomed Anal 14: 23-31.
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Cragg%20GM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlushttp://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Newman%20DJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlusjavascript:AL_get(this,%20'jour',%20'J%20Ethnopharmacol.');javascript:AL_get(this,%20'jour',%20'J%20Ethnopharmacol.');
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
284
Dadgar, D., Burnett, P.E., Choc, M.G., Gallicano, K., Hooper, J.W., 1995. Application
issues in bioanalytical method validation, sample analysis and data reporting. J
Pharm Biomed Anal 13(2): 89-97.
Darvas, F., Keseru, G., Papp, A., Dorman, G., Urge, L., Krajcsi, P., 2002. In Silico and
Ex silico ADME approaches for drug discovery. Curr Top Med Chem 2(12):
1287-304.
Dass, C., 1999. Recent developments and applications of high-performance liquid
chromatography-electro spray ionization mass spectrometry. Curr Org Chern 3:
193-200
Davies, B., Morris, T., 1993. Physiological parameters in laboratory animals and
humans. Pharm Res. 10: 1093.
Decker, S., Hollingshead, M., Bonomi, C.A., Carter, J.P., Sausville, E.A., 2004. The
hollow fibre model in cancer drug screening; the NCI experience. Eur J Cancer
40: 821–6.
Delie, F., Rubas, W., 1997. A human colonic cell sharing similarities with enterocytes as
a model to examine oral absorption advantages and limitations of the Caco-2
model. Crit. Rev. Ther Drug Carrier Syst 14: 221-286.
Deng, Y., Synder, J.K., 2002. Preparation of a 24-nor-1,4-dien-3-one triterpene
derivatives from betulin: a new route to 24-nortriterpene analogues. J Organ
Chem 67: 2864-2873.
Deng, Y.X., Lu, T., Xie, L., Liu, X.D., 2005. Biomed Chromatogr 20: 1098–1002.
Dokoumetzidis, A., Kalantzi, L., Fotaki, N., 2007. predictive models for oral drug
absorption : from in silico methods to integrated dynamical models. Expert Opin
Drug Metab Toxicol 3(4): 491.
Donehower, L.A., Harvey, M., Slagle, B.L., 1992. Mice deficient for p53 are
developmentally normal but susceptible to spontaneous tumours. Nature 356:
215–21.
Draft guidance for industry: drug interaction studies—study design, data analysis, and
implications for dosing and labeling.
http://www.fda.gov/cder/guidance/6695dft.pdf.
http://www.ncbi.nlm.nih.gov/pubmed?term=Darvas%20F%5BAuthor%5D&cauthor=true&cauthor_uid=12470281http://www.ncbi.nlm.nih.gov/pubmed?term=Keseru%20G%5BAuthor%5D&cauthor=true&cauthor_uid=12470281http://www.ncbi.nlm.nih.gov/pubmed?term=Papp%20A%5BAuthor%5D&cauthor=true&cauthor_uid=12470281http://www.ncbi.nlm.nih.gov/pubmed?term=Dorm%C3%A1n%20G%5BAuthor%5D&cauthor=true&cauthor_uid=12470281http://www.ncbi.nlm.nih.gov/pubmed?term=Urge%20L%5BAuthor%5D&cauthor=true&cauthor_uid=12470281http://www.ncbi.nlm.nih.gov/pubmed?term=Krajcsi%20P%5BAuthor%5D&cauthor=true&cauthor_uid=12470281http://www.ncbi.nlm.nih.gov/pubmed/12470281http://www.fda.gov/cder/guidance/6695dft.pdf
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
285
Durrence, C.W., DiPiro, J.T., May, J.R., 1985. Potential drug interactions in surgical
ptients. Am J Hosp Pharm 42: 1553-1555.
Ekins, S., Ring, B.J., Grace, J., McRobie-Belle, D.J., Wrighton, S.A., 2000. Present and
future in vitro approaches for drug metabolism . J pharmacol Toxicol Methods
44(1): 313.
Ekins, S., Waller, C.L., Swaan, P.W., Cruciani, G., Wrighton, S.A., Wikel, J.H., 2000.
Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol
Methods 44(1): 251-72.
El Hilali, N., Rubio, N., Martinez-Villacampa, M., Blanco, J., 2002. Combined
noninvasive imaging and luminometric quantification of luciferase-labeled
human prostate tumors and metastases. Lab Invest 82: 1563–71.
Evans, G.H., Shand, D.G., 1973. Disposition of propanolol, Drug accumulation and
steady state concentrations during chronic oral administration in man. Clin
Pharmacol Therap 14: 487.
Evers, M., Poujade, C., Soler, F., Ribeill, Y., James, C., Lelievre, Y., Gueguen, J.C.,
Residorf, D., Morize, I., Pauwels, R., Clercq, D.E., Henin, Y., Bousseau, A.,
Mayaux, F.J., Pecq, B.J., Dereu, N., 1996. Betulinic Acid derivatives: A new
class of human immunodeficiency virus type I Specific inhibitors with a new
mode of action. J Medicin Chem 39: 1056-1068.
FDA., 1999. Guidance for Industry. In vivo drug metabolism/drug interaction studies-
study design, data analysis, and recommendations for dosing and labeling.
www.fda.gov/cder/guidance
Fidler, I.J., 1986. Rationale and methods for the use of nude mice to study the biology
and therapy of human cancer metastasis. Cancer Metastasis Rev 5: 29–49.
Fidler, I.J., Naito, S., Pathak, S., 1990. Orthotopic implantation is essential for the
selection, growth and metastasis of human renal cell cancer in nude mice
[corrected]. Cancer Metastasis Rev 9: 149–65.
Fiebig, H. H., Schmid, J. R., Bieser, W., Henss, H., and Löhr, G. W., 1987. Colony assay
with human tumor xenografts, murine tumors and human bone marrow.
Potential for anticancer drug development. Eur J Cancer Clin Oncol 23: 937–
948.
http://www.ncbi.nlm.nih.gov/pubmed?term=Ekins%20S%5BAuthor%5D&cauthor=true&cauthor_uid=11274894http://www.ncbi.nlm.nih.gov/pubmed?term=Waller%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=11274894http://www.ncbi.nlm.nih.gov/pubmed?term=Swaan%20PW%5BAuthor%5D&cauthor=true&cauthor_uid=11274894http://www.ncbi.nlm.nih.gov/pubmed?term=Cruciani%20G%5BAuthor%5D&cauthor=true&cauthor_uid=11274894http://www.ncbi.nlm.nih.gov/pubmed?term=Wrighton%20SA%5BAuthor%5D&cauthor=true&cauthor_uid=11274894http://www.ncbi.nlm.nih.gov/pubmed?term=Wikel%20JH%5BAuthor%5D&cauthor=true&cauthor_uid=11274894http://www.ncbi.nlm.nih.gov/pubmed/11274894http://www.ncbi.nlm.nih.gov/pubmed/11274894http://www.fda.gov/cder/guidance
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
286
Fiebig, H.H., 2004. Clonogenic assay with established human tumour xenografts:
correlation of in vitro to in vivo activity as a basis for anticancer drug discovery.
Eur J Cancer 40: 802–820.
Fluda, S., Scaffidi, C., Susin, S.A., Krammer, P.H., Kroemer, G., Peter, M.E., Dabtain,
K.M., 1998. Activation of mitochondria and release of mitochondrial
apoptogenic factors by betulinic acid. J Biol Chem 273(51): 33942-33948.
Fraga, M., 1990. Effect of type of fibre on the rate of passage and on the contribution of
soft feces to nutrient intake of finishing rabbits. Journal of Animal Science 69:
1566.
Freitas, L.G., G'otz, C.W., Ruff, M., Singer, H.P., M''uller, S.R., 2004. Quantification of
the new triketone herbicides, sulcotrione and mesotrione, and other important
herbicides and metabolites, at the ng/l level in surface waters using liquid
chromatographytandem mass spectrometry. J Chromatogr A 1028: 277-282.
Frick, L.W., Adkision, K.K., Knecht, K.J.W., Woollard, P., Higton. D.M., 1998. Cassette
dosing: rapid estimation of in vivo pharmacokinetics. Med Chem Res 8: 472-
477.
Frick, L.W., Adkision, K.K., Knecht, K.J.W., Woollard, P., Higton, D.M., 1998a.
Cassette dosing: rapid in vivo assessment of pharmacokinetics. Pharmaceut Sci
Technol Today 1: 12-18.
Friedman, M.A., Woodcock, J., Lumpkin, M.M., Shuren, J.E., Hass, A.E., Thompson,
L.J., 1999. The safety of newly approved medicines: do recent market removals
mean there is a problem. JAMA 281(18): 1728-34.
Frimmer, M., 1987. What we have learned from phalloidin. Tox Lett 35: 169-182.
Frimmer, M., 1989. Uptake of foreign cyclopeptides by liver cells. In: Hepatic Transport
of Organic Substances, E., Petzinger, R.K.H., Kinne, H., Sies, (eds). Springer-
Verlag, Berlin, Heidelberg.
Frimmer, M., and Ziegler, K., 1988. The transport of bile acids in liver cells. Biochem
Biophys Acta 947: 75-99.
Fu, I., Woolf, E., Matuszewski, B., 1998. Effect of the sample matrix on the
determination of indinavir in human urine by HPLC with turbo ion spray
tandem mass spectrometric detection. J Pharmaceut Biomed Anal 18: 347-357.
http://www.ncbi.nlm.nih.gov/pubmed?term=Friedman%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Woodcock%20J%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Lumpkin%20MM%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Shuren%20JE%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Hass%20AE%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Thompson%20LJ%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Thompson%20LJ%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Friedman%20MA%201999%20the%20safety%20of%20newly%20approved%20medicine
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
287
Fulda, S., Debatin, K.M., 2000. Betulinic acid induces apoptosis through a direct effect
on mitochondria in neuroectodermal tumors. Med Pediatr Oncol 35: 616–618.
Fulda, S., Debatin, K.M., 2005. Sensitization for anticancer drug-induced apoptosis by
betulinic Acid. Neoplasia 7: 162-170.
Fulda, S., Friesen, C., Los, M., Scaffidi, C., Mier, W., Benedict, M., Nunez, G.,
Krammer, P.H., Peter, M.E., Debatin, K.M., 1997. Betulinic acid triggers CD95
(APO-1/Fas)- and p53-independent apoptosis via activation of caspases in
neuroectodermal tumors. Cancer Res 57: 4956–4964.
Fulda, S., Jeremias, I., Steiner, H.H., Pietsch, T., Debatin, K.M., 1999. Betulinic acid: A
new cytotoxic agent against malignant brain-tumor cells. Int J Cancer 82: 435–
441.
Fulda, S., Scaffidi, C., Susin, S.A., Krammer, P.H., Kroemer, G., Peter, M.E., Debatin, K-
M., 1998. Activation of mitochondria and release of mitochondrial apoptogenic
factors by betulinic acid. J Biol Chem 273: 33942–33948.
Gabizon, G., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., 1994.
Prolonged circulation time and enhanced accumulation in malignant exudates of
doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res
54: 987-992.
Gabizon, G., Papahadjopoulos, D., 1988. Liposome formulation with pro-longed
circulation time in blood and enhanced uptake by tumors. Proc Nat Acad Sci 85:
6949-6953.
Galgon, T., Wohlrab, W., Drager, B., 2005. Betulinic acid induces apoptosis in skin
cancer cells and differentiation in normal human keratinocytes. Exp Dermatol
14: 736-743.
Gan, L.S.L., Thakker, D.R., 1997. Application of the Caco-2 model in the design and
development of orally active drugs: elucidation of biochemical and physical
barriers posed by the intestinal epithelium. Adv Drug Deliv Rev 23: 77-98.
Ganesan, M., Nanjundan, S., Rauthan, K.S., Eswaran, K., 2010. Rapid analysis of
labetalol in human plasma using liquid chromatography tandem mass
spectrometry, International Journal of Pharmaceutical Sciences and Research
1: 209-218.
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
288
Gastearena, I., Dios-Vieitez, M.C., Terraz, M.M., Domingo, S., Fos, D., 1995.
Determination of the alpha1-acid glycoprotein binding of azithromycin in vitro
by equilibrium dialysis. J Chemother 4(7): 26-8.
Gibaldi, M., Boyes, R.N., Feldman, S., 1971. Influence of the first pass effect on the
availability of drugs on oral administration. J Pharm Sci 60: l338.
Gibaldi, M., Perrier, D., 1982. Pharmacokinetics, Marcel Dekkar Inc.: New York, 369.
Gidenne, T., 1992. Effect of fibre level, particle SIze and adaptation period on
digestibility and rate of passage as measured at the ileum and in the faeces in
the adult rabbit. British Journal of Nutrition 67: 133.
Gilbert, J.D., Olah, T.V., Barrish, A., Greber, T.F., 1992. Determination ofL-654,066, a
new 5 alpha-reductase inhibitor in plasma by /liquid
chromatography/atmospheric pressure chemical ionization mass spectrometry.
Biol Mass Spectrorn 21: 341-346.
Gombar, V.K., Silver, I.S., Zhao, Z., 2003. Role of ADME characteristics in drug
discovery and their in silico evaluation : in silico screening of chemicals for
their metabolic stability. Curr Top Med Chem 3 (11): 1205-1225.
Gorelik, E., Ovejera, A., Shoemaker, R., 1987. Microencapsulated tumor assay: new
short-term assay for in vivo evaluation of the effects of anticancer drugs on
human tumor cell lines. Cancer Res 47: 5739–47.
Gregus, Z., Klaassen, C.D., 1986. Enterohepatic circulation of toxicants. In:
Gastrointestinal Toxicity, K., Rozman, and O., Hanninen, (eds). Elsevier,
Amsterdam, 57-188.
Guengerich, F.P., Macdonald, T.L., 1990. Mechanisms of cytochrome P-450 catalysis.
FASEB J 4: 2453-2459.
Guengerich, F.P., 1993. The 1992 Bernard B Brodie award lecture. Bioactivation and
detoxication of toxic and carcinogenic chemicals. Drug Metab Dispos 2: 1-5.
Guidance for Industry, 2001. Mass Spectrometry for Confirmation of the identity of
Animal Drug Residues, Draft Guidance. US Department of Health and Human
Services, Food and Drug Administration: Washington, DC.
Guidance for Industry: Bioanalytical Method Validation, 2001. U.S. Department of
Health and Human Services, Food and Drug Administration Centre for Drug
Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM).
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
289
Guo, B., Li, C., Deng, Z., Chen, S., Ji, Z., Zhang, J., Chen, M., Xu, F., 2005. A new
method for measurement of (-)-sophocarpine, a candidate therapeutic for viral
myocarditis, in plasma: application to a toxicokinetic study in beagle dogs. Rap
Commun Mass Spectromet 19: 2840-2848.
Guttendorf, R.J., Andress, L., Okonkwo, G., Lesch, M., Finkel, M., Schrier, D., Loewen,
G., 1992. Pharmacokinetic and pharmacodynamic assessment of a novel
antiinflammatory drug in early discovery. Pharm Res 9: S- 356.
Harris, P.A., Riegelman, S., 1969. Influence of the route of administration on the area
under the plasma-concentration-time curve. J Pharm Sci 58: 71.
Hartmann, C., Smeyers-Verbeke, J., Massart, D.L., McDowall, R.D., 1998. Validation of
bioanalytical chromatographic methods. J Pharm Biomed Anal 17:1 93-218.
Hasegawa, T., Saneyioshi, N., Kawaguchi, T., 1996. Intestinal absorption and first pass
metabolism of 2, 3,-dideoxynucleotides following oral administration in rats.
Bio Pharm Bull 19: 599.
Hastings, K.L., El-Hage, J., Jacobs, A., Leighton, J., Morse, D., Osterberg, R., 2003.
Toxicol Appl Pharmacol 190: 91–92.
Hata, K., Hori, K., Takahashi, S., 2002. Differentiation- and apoptosis-inducing activities
by pentacyclic triterpenes on a mouse melanoma cell line. J Nat Prod 65: 645–
648.
Hawksworth, G.M., 1994. Advantages and disadvantages of using human cells for
pharmacological and toxicological studies. Hum Exp Tox 13: 568-573.
Hayon, T., Dvilansky, A., Shpilberg, O., Nathan, I., 2003. Appraisal of the MTT-based
assay as a useful tool for predicting drug chemosensitivity in leukemia. Leuk
Lymphoma 44: 1957–1962.
Hedman, A., Angelin, B., Ardvisson, A., Beck, O., Dahlqvist, R., Nilsson, B., Olsson, M.,
Schenk-Gustafsson, K., 1991. Digoxin-verapamil interaction: Reduction of
biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 49: 256-
262.
Henion, J., Brewer, E., Rule, G., 1998. Sample preparation for LC/MS/MS: analyzing
biological and environmental samples. Anal Chern 70: 650-656.
Heykants, J., Meuldermans, W., 1994. Nonclinical Kinetics and Metabolism Studies in
Support of the Safety Assessment of Drugs. Drug Information Journal 28: 163-
172.
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
290
Hidalgo, I.J., 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a
model system for intestinal epithelial permeability. Gastroenterology 96: 736-
749.
Hladky, S.B., 1990. Pharmacokinetics. Manchester University Press, Manchester, New
York.
Hoener, B-A., 1994. Predicting the hepatic clearance of xenobiotics in humans from in
vitro data. Biopharm Drug Disp 15: 295-304.
Hoffman, R.M., 1997. Fertile seed and rich soil: The development of clinically relevant
models of human cancer by surgical orthotopic implantation of intact tissues. In:
Teicher B, editor. Anticancer drug development guide: preclinical screening,
clinical trials, and approval. Totowa, N.J., Humana Press, Inc. 127–44.
Hoffman, R.M., 1999. Visualisation of metastasis in orthotopic mouse models with green
fluorescent protein. In: Fiebig, H.H., Burger, A.M., editors. Relevance of
tumour models for anticancer drug development. Contrib Oncol. 54: 81–7.
Hollingshead, M.G., Alley, M.C., Camalier, R.F., 1995. In vivo cultivation of tumor cells
in hollow fibers. Life Sci 57:131–41.
Houston, J.B., 1994. Utility of in vitro drug metabolism data in predicting in vivo
metabolic clearance. Biochem Pharmacol 47: 1469-1479.
Huang, S.M., Strong, J.M., Zhang, L., Reynolds, K.S., Nallani, S., Temple, R., Abraham,
S., Al, H.S., Baweja, R.K., Burckart, G.J., Chung, S., Colangelo, P., Frucht, D.,
Green, M.D., Hepp, P., Karnaukhova, E., Ko, H.S., Lee, J.I., Marroum, P.J.,
Norden, J.M., Qiu, W., Rahman, A., Sobel, S., Stifano, T., Thummel, K., Wei,
X.X., Yasuda, S., Zheng, J.H., Zhao, H., Lesko, L.J., 2008. New era in drug
interaction evaluation: US food and drug administration update on CYP
enzymes, transporters, and the guidance process. J Clin Pharmacol 48(6): 662–
670.
Huang, S.M., Temple, R., Throckmorton, D.C., Lesko, L.J. 2007. Drug interaction
studies: study design, data analysis, and implications for dosing and labeling.
Clin Pharmacol Ther 81(2): 298–304.
Hubbard, W., Bickel, C., Scheimer, R.P., 1994. Simultaneous Quantitation of
Endogenous Levels of Cortisone and Cortisol in Human Nasal and
Bronchoalveolar Lavage Fluids and Plasma via Gas Chromatography-Negative
Ion Chemical Ionization Mass Spectrometry. Anal Biochem 221: 109-117.
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
291
Humphrey, M.J., 1989. Pharmacokinetic studies in the selection of new drugs: a case
history on dihydropyridine calcium channel blockers. in Xenobiotic Metabolism
and Disposition, eds Kato, R., Estahrook, R.W., Gayen M.N., (Taylor & Francis,
New York), 245–253.
Humphreys, W.G., Unger, S.E., 2006. Chem Res Toxicol 19: 1564–1569.
Hunter, J., Hirst, B.H., Simmons, N.L., 1993. Transepithelial secretion, cellular
accumulation and cytotoxicity of vinblastine in defined MDCK cell strains.
Biochim Biophys Acta 1179: 1-10.
Huss, W.J., Maddison, L.A., Greenberg, N.M., 2001. Autochthonous mouse models for
prostate cancer: past, present and future. Semin Cancer Biol 11: 245–60.
ICH Q2 (R1), 1995. Note for guidance on validation of analytical procedures
(CPMP/ICH/38/95)
Imre, S., Vlase, L., Muntean, D.L., 2008. Bioanalytical method validation, Revista
Romana de Medicina de Laborator 10: 13-21.
Indap, M.A., Ambaye, R.Y., 1991. Efficacy of 5-fluorouracil in combination with
methoxyphenyl maleamic acid in murine tumors. J Postgrad Med 37(4): 211-
215.
Inui, K-I., Yamamoto, M., Saito, H., 1992. Transepithelial transport of oral
cephalosporins by monolayers of intestinal epithelial cell line CaCO-2:
specific transport systems in apical and basolateral membranes. J Pharmacol
Exp Ther 261: 195-201.
Irvine, J.D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J.W., Selick, H.E., Grove,
J.R., 1999. MDCK (Madin-Darby canine kidney) cells: A tool for membrane
permeability screening. J Pharm Sci 88: 28-33.
Ishihara, M., Sakagami, H., Liu, W.K.K. 2005. Quantitative Structure-Cytotoxicity
Relationship Analysis of Betulinic Acid and its Derivatives by Semi-empirical
Molecular-orbital Method, Anticancer Research 25: 3951-3956
Issar, M., Singh, S.K., Mishra, B., Gupta, R.C., 2003. Pharmacokinetics, insitu
absorption and protein binding studies of new neuroleptic agent centbutindole
in rats. Eur J Pharm Sci 19: 105.
Jaggi, M., Mukherjee, R., 1995. Establishment of tumorogenic cell lines from biopsies of
human colon adenocarcinoma. J Appl Biomed 3: 27-35.
javascript:AL_get(this,%20'jour',%20'J%20Postgrad%20Med.');
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
292
Jang, G.R., Harris, R.Z., Lau, D.T., 2001. Pharmacokinetics and its role in smass
molecule drug discovery research. Med Res Rev 21(5): 382.
Jansen, P.L.M., Oude-Elferink, R.P.J., 1993. Defective hepatic anion secretion in mutant
TR- rats. In: Hepatic Transport and Bile Secretion: Physiology and
Pathophysiology, distribution and elimination of drugs with special ref erences
to the category of organic cations. J Pharmaco Biopharm 18: 35-70.
Jeong, H.J., Chai, H.B., Park, S.Y., Kim, D.S., 1999. Preparation of amino acid
conjugates of betulinic acid with activity against human melanoma. Bioorgan
Med Chem Lett 9: 1201-1204.
Jeong, T.S., Hwang, E.I., Lee, H.B., Lee, E.S., Kim, Y.K., Min, B.S., Bae, K.H., Bok,
S.H., Kim, S.U., 1999. Chitin synthase II inhibitory activity of ursolic acid,
isolated from Crataegus pinnatifida. Planta Med 65: 261–263.
Jerry, Z.Y., Weiqing, C., Ronald, T.B., 2002. In Vitro Stability and In Vivo
Pharmacokinetic Studies of a Model Opioid Peptide, H-Tyr-D-Ala-Gly-Phe-D-
Leu-OH (DADLE), and Its Cyclic Prodrug. Pharmacology 303: 840-848.
Jia, L., Blantz, R.C., 1998. Eur J Pharmacol 354: 33–41.
Jia, L., Coward, L.C., Kerstner-Wood, J., Gorman, G., Noker, P., Kitada, S., Pellecchia,
M.P., Reed, J.C., 2007. Cancer Chemother Pharmacol 60: 570–80.
Jia, L., Noker, P.E., Coward, L., Gorman, G., Protopopova, M., Tomaszewski, J.E., 2006.
Br J Pharmacol 147: 476–485.
Jia, L., Tomaszewski, J.E., Noker, P.E., Gorman, G.S., Glaze, E., Protopopova, M., 2005.
J Pharm Biomed Anal 37: 23–33.
Jia, L., Wong, H., Wang, Y., Garza, M., Weitman, S.D., 2003. J Pharm Sci 92: 161–172.
Jia, L., Young, X., Guo, W., 1999. J Pharm Sci 88: 981–986.
Jia, L., Yu, L., Linnik, D.M., Jack, R.M., 2001. J Pharm Pharmacol 53: 999–1005.
Jia. L., Schweikart, K., Tomaszewski, J., Reed, J., Ames, M., Page, J., Noker, P., Munn,
D., 2007. Food Chem Toxicol 68-73.
Jiunn, H., Lin, Anthony, Y. H. L., 1997. Role of Pharmacokinetics and Metabolism in
Drug Discovery and Development, Pharmacological Reviews 49: 4 403-449.
Kamalraj, R., Devdass, G., Rajalakshimi, V., Nithin, J., 2012. Bioanalytical method
development models and validation for drug and its metabolite by using
LCMS/MS: An review, Journal of Pharmacy Research 5: 377-380.
http://pharmrev.aspetjournals.org/search?author1=Jiunn+H.+Lin&sortspec=date&submit=Submithttp://pharmrev.aspetjournals.org/search?author1=Anthony+Y.+H.+Lu&sortspec=date&submit=Submit
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
293
Kamimoto, Y., Gatmaitan, Z., Hsu, J., Arias, I.M., 1989. The function of Gp 170
multidrug resistance gene product. in rat liver canalicular membrane vesicles. J
Biol Chem 264: 11693-11698.
Kansey, M., Fische, H., Kratzat, K., Senner, F., Wagner, B., Parrilla, I., 2001. High-
throughput artificial membrane permeability studies in early lead discovery and
development. Pharmacokinet. Optim Drug Res 11: 448-464.
Kansey, M., Senner, F., Gubernator, K., 1998. Physiochemical high throughput screening:
parallel artificial membrane permeation assay in the description of passive
absorption process. J Med Chem 41: 1007-1010.
Kariv, I., Rourick, R.A., Kassel, D.B., Chung, T.D., 2002. Improvement of "hit-to-lead"
optimization by integration of in vitro HTS experimental models for early
determination of pharmacokinetic properties. Comb Chem High Throughput
Screen 5(6):459-72.
Karlsson, M.O., Bredberg, U., 1989. Estimation of bioavailability on a single occasion
after semisimultaneous drug administration. Pharm Res 6: 817-821.
Kasperczyk, H., La, Ferla-Bruhl, K., Westhoff, M.A., Behrend, L., Zwacka, R.M.,
Debatin, K.M., 2005. Betulinic acid as new activator of NF-kappaB: molecular
mechanisms and implications for cancer therapy. Oncogene 24: 6945-6956.
Kassel, D.B., 2004. Applications of high-throughput ADME in drug discovery. Curr
Opin Chem Biol 8(3): 339-45.
Katya, T., Michel, B., Aloise, M., 2009. The Alzheimer's Drug Discovery Foundation.
ADDME – Avoiding Drug Development Mistakes Early: central nervous system
drug discovery perspective. BMC Neurology 9(Suppl 1): S1.
Kelland, L.R., 2004. Of mice and men: values and liabilities of the athymic nude mouse
model in anticancer drug development. Eur J Cancer 40: 827–36.
Kerbel, R.S., 2003. Human tumor xenografts as predictive preclinical models for
anticancer drug activity in humans: better than commonly perceived—but they
can be improved. Cancer Biol Ther 2: S134–9.
Kerns, E., Di, L., Petusky, S., Farris, M., Ley, R., Jupp, P., 2004 Combined application of
parallel artificial membrane permeability assay and Caco-2 permeability assays
in drug discovery. J Pharm Sci 93:1440–1453.
Khurana, M., Lala, J., Singh, M.M., Paliwal, J.K., Kamboj, V.P., Gupta, R.C., 2002.
http://www.ncbi.nlm.nih.gov/pubmed?term=Kariv%20I%5BAuthor%5D&cauthor=true&cauthor_uid=12470275http://www.ncbi.nlm.nih.gov/pubmed?term=Rourick%20RA%5BAuthor%5D&cauthor=true&cauthor_uid=12470275http://www.ncbi.nlm.nih.gov/pubmed?term=Kassel%20DB%5BAuthor%5D&cauthor=true&cauthor_uid=12470275http://www.ncbi.nlm.nih.gov/pubmed?term=Chung%20TD%5BAuthor%5D&cauthor=true&cauthor_uid=12470275http://www.ncbi.nlm.nih.gov/pubmed/12470275http://www.ncbi.nlm.nih.gov/pubmed/12470275http://www.ncbi.nlm.nih.gov/pubmed?term=Kassel%20DB%5BAuthor%5D&cauthor=true&cauthor_uid=15183334http://www.ncbi.nlm.nih.gov/pubmed/15183334http://www.ncbi.nlm.nih.gov/pubmed/15183334
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
294
Evaluation of interaction potential of certain concurrently administered drugs
with pharmacological and pharmacokinetic profile of centchroman in rats.
Contraception 66: 47.
Killion, J.J., Radinsky, R., Fidler, I.J., 1999. Orthotopic models are necessary to predict
therapy of transplantable tumors in mice. Cancer Metastasis Rev 17: 279–84.
Kim YJ, Koo MH and Kim DS. (2001) Development of C-20 modified betulinic acid
derivatives as antitumor agents. Bioorgan Med Chem Lett 11: 2405-2408.
Kim, D.S.H.L., Pezzuto, J.M., Pisha, E., 1998. Synthesis of betulinic acid derivatives with
activity against human melanoma. Bioorg Med Chem Lett 8: 1707–1712.
Kim, Y.J., Koo, M.H., Kim, D.S., 2001. Development of C-20 modified betulinic acid
derivatives as antitumor agents. Bioorgan Med Chem Lett 11: 2405-2408.
King, R., Bonfiglio, R., Fernandez-Metzler, C., Miller-Stein, C., Olah, T., 2000.
Mechanistic investigation of ionization suppression in electrospray ionization. J
American Societ Mass Spectromet 11: 942-950.
Kinoshita, K., Yang, Y., Koyama, K., Takahashi, K., Nishino, H., 1999. Inhibitory effect
of some triterpenes from cacti on 32P-incorporation into phospholipids of HeLa
cells promoted by 12-O-tetradecanoylphorbol-13- acetate. Phytomedicine 6: 7
3–77.
Kitamura, R., Matsuoka, K., Matsushima, E., Kawaguchi, Y., 2001. Improvement
precision of the liquid chromatographic-electro spray ionization tandem mass
spectrometric analysis of 3 '-C-ethynylcytidine in rat plasma. J Chromatogr B
754: 113-119.
Klassen, C.D., Watkins J.B., 1984. Mechanisms of bile formation, hepatic uptake and
biliary excretion. Pharmacol Rev 36: 313.
Kommera, H., Kaluđerović, G.N., Kalbitz, J., Paschke, R., 2011. Lupane
Triterpenoids— Betulin and Betulinic acid derivatives induce apoptosis in
tumor cells, Invest New Drugs 29: 266–272.
Kostiainen, R., Kotiaho, T., Kuuranne, T., Auriola, S., 2003. J Mass Spectrom 38: 357–
372.
Kouzi, S.A., Chatterjee, P., Pezzuto, J.M., Hamann, M.T., 2000. Microbial
transformations of the antimelanoma agent betulinic acid. J Nat Prod 63: 1653–
1657.
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
295
Kronbach, T., Mathys, D., Gut, J., Catin, T., Meyer, U.A., 1987. High-performance liquid
chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-
hydroxylase, and dextromethorphan O-demethylase in microsomes and purified
cytochrome P-450 isozymes of human liver. Anal Biochem 162(1): 24-32.
Krzyzanski, W., Jusko, W.J., 1998. Characterization of pharmacodynamic recession
slopes for direct and indirect response models. J Pharmacokin Biopharm 26:
409-436.
Kubinyi, H., 2003. Drug research: myths, hype and reality. Nat Rev Drug Discov 2: 665–
668.
Kumar, V., Rani, N., Aggarwal, P., Sanna, V.K., Singh, A.T., Jaggi, M., Joshi, N.,
Sharma, P.K., Irchhaiya, R., Burman, A.C., 2008. Synthesis and cytotoxic
activity of heterocyclic ring-substituted betulinic acid derivatives. Bioorgan
Med Chem Lett 18: 5058-5062. DOI:1016/j.bmcl.2008.08.003.
Kurz, J., Trunk, J., Weitz, B., 1977. Evaluation of methods to determine protein binding
of drugs, equilibrium dialysis, ultrafiltration, ultracentrifugaion and gel
filtration. Drug Res 27: 1373.
Kvasnica, M., Sarek, J., Klinotova, E., Dzubak, P., Hajduch, M., 2005. Synthesis of
phthalates of betulinic acid and betulin with cytotoxic activity. Bioorg Med
Chem 13: 3447-3454.
Kwon, H.J., Shim, J.S., Kim, J.H., Cho, H.Y., Yum, Y.N., Kim, S.H.,Yu, J., 2002.
Betulinic acid inhibits growth factor-induced in vitro angiogenesis via the
modulation of mitochondrial function in endothelial cells. Jpn J Cancer Res 93:
417–425.
Lacy, P.E., Hegre, O.D., Gerasimidi-Vazeou, A., Gentile, F.T., Dionne, K.E., 1991.
Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of
encapsulated islets. Science 254: 1785–4.
Lagana, A., Fago, G., Marino, A., Santarelli, D., 2001. Liquid chromatography tandem
mass spectrometry applied to the analysis of natural and synthetic steroids in
environmental waters. Anal Lett 34: 913-925.
Lahoz, A., Gombau, L., Donato, M.T., Castell, J.V., Gomez-Lechon, M.J., 2006. Invitro
ADME medium /high –throughput screening in drug preclinical development.
Mini Rev M ed Chem 6(9):1053.
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
296
Lan, P., Chen, W.N., Huang, Z.J., Sun, P.H., Chen, W.M., 2011. Understanding the
structure- activity relationship of betulinic acid derivatives as anti-HIV-1
agents by using 3D- QSAR and docking. J Mol Model 17: 1643–1659.
Lanza, R.P., Butler, D.H., Borland, K.M., 1991. Xenotransplantation of canine, bovine,
and porcine islets in diabetic rats without immunosuppression. Proc Natl Acad
Sci 88: 11100–4.
Lasser, K.E., Allen, P.D., Woolhandler, S.J., Himmelstein, D.U., Wolfe, S.M., Bor, D.H.,
2002. Timing of new black box warnings and withdrawals for prescription
medications. JAMA 287(17): 2215-20.
Lave, T., Dupin, S., Schmitt. C., Valles, B., Ubeaud, G., Chou, R.C., Jaeck, D., Coassolo,
P., 1997. The use of human hepatocytes to select compounds based on their
expected hepatic extraction ratios in humans. Pharm Res 14: 152-155.
Leahy, D.E., Lynch, J., Taylor, D.D., 1989. Mechanisms of absorption of small
molecules. in Novel Drug Delivery, eds Prescott, L.F., Nimmo, W.S., (John
Wiley & Sons, New York), 33–44.
Lee, J.S., Min, B.S., Bae, K.H., 1996. Cytotoxic constituents from the Forsythiae fructus
against L1210 and HL60 cells. Yakhak Hoeji 40: 462–467.
Lee, K.H., 1999. Anticancer Drug Design Based on Plant-Derived Natural Products. J
Biomed Sci 6(4): 236–250.
Lee, M.S., Kerns. E.H. 1999. LC/MS applications in drug development. Mass Spectrom
Rev 18: 187-279.
Lee, P.H., Cucurull-sanchez, L., Lu, J., Du, Y.J., 2007. Development of in silico models
for human liver microsomal stability. J Comput Aided Mol Des (epub ahead of
print).
Li, A.P., 2001. Screening for human ADME/Tox drug properties in drugdiscovery. Drug
Discovery Today (6)7: 357–366.
Li, A.P., 2004. In vitro approaches to evaluate ADMET drug properties .Curr Top Med
chem 4(7): 701.
Liang, H.R., Takagaki, T., Foltz, R.L., Bennett, P., 2005. Quantitative determination of
endogenous sorbitol and fructose in human nerve tissues by atmospheric-
http://www.ncbi.nlm.nih.gov/pubmed?term=Lasser%20KE%5BAuthor%5D&cauthor=true&cauthor_uid=11980521http://www.ncbi.nlm.nih.gov/pubmed?term=Allen%20PD%5BAuthor%5D&cauthor=true&cauthor_uid=11980521http://www.ncbi.nlm.nih.gov/pubmed?term=Woolhandler%20SJ%5BAuthor%5D&cauthor=true&cauthor_uid=11980521http://www.ncbi.nlm.nih.gov/pubmed?term=Himmelstein%20DU%5BAuthor%5D&cauthor=true&cauthor_uid=11980521http://www.ncbi.nlm.nih.gov/pubmed?term=Wolfe%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=11980521http://www.ncbi.nlm.nih.gov/pubmed?term=Bor%20DH%5BAuthor%5D&cauthor=true&cauthor_uid=11980521http://www.ncbi.nlm.nih.gov/pubmed?term=Lasser%20KE%202002%20timing%20of%20new%20black%20box
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
297
pressure chemical ionization liquid chromatography/tandem mass spectrometry.
Rap Commun Mass Spectromet 19: 2284-2294.
Libby, K., Marcy, E., 2007. Automation of Cell-Based and Noncell-Based Permeability
Assays, Journal of Laboratory Automation 12(2): 104-109.
Lin, J., Sahakian, D.C., de, M.S.M., Xu, J.J., Polzer, R.J., Winter, S.M., 2003. The role of
absorption, distribution, metabolism, excretion and toxicity in drug discovery.
Curr Top Med Chem 3(10): 1125-54.
Lin, J.H., 1994. Dose dependent pharmacokinetics: Experimental observations and
theoretical considerations. Biopharm Drug Dispos. 15: 1.
Lin, J.H., 1995. Species similarities and differences in pharmacokinetics . Drug Metab
Dispos 23(10): 1008.
Lin, J.H., 1996a. Bisphosphonates: a review of their pharmacokinetic properties. Bone
18: 75–85.
Lin, J.H., Lu, A.Y., 1997. Role of Pharmacokinetics and metabolism in Drug Discovery
and Development. Pharmacol Rev 49(4): 403-449.
Lin, J.H., Storey, D.E., Chen, I.W., Xu, X., 1996c. Improved oral absorption of L-
365,260, a poorly soluble drug. Biopharm. Drug Dispos 17: 1–16.
Lindner, W., Wainer, I.W., 1998. Requirements for initial assay validation and
publication in J Chromatography B 707: 1-2.
Lipinski, C., Lombardo, F., Dominy, B., Feeney, P., 2001. Experimental and
computational approaches to estimate solubility and permeability in drug
discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
Lippi, A., Crieuoli, M., Guelfi, M., Santicioli, M., Maggi, C.I., 1998. Pharmacokinetics of
bicyclic peptide tachykinin NK2 receptor antagonist MEN 11420 (Nepadutant)
in rats. Drug Metab Dispos 26: 1077.
Litterst, C.L., Minnaugh, E.G., Reagon, R.L., Gram, T.E., 1975. Comparison of in vitro
drug metabolism by lung, liver and kidney of several common laboratory
species. Drug Metab Dispos 3: 259.
Liu, X.D., Xie, L., Gao, J.P., Lai, L.S., Liu, G.Q., 1997. Eur J Drug Metab
Pharmacokinet 22: 185–188.
http://www.ncbi.nlm.nih.gov/pubmed?term=Lin%20J%5BAuthor%5D&cauthor=true&cauthor_uid=12769713http://www.ncbi.nlm.nih.gov/pubmed?term=Sahakian%20DC%5BAuthor%5D&cauthor=true&cauthor_uid=12769713http://www.ncbi.nlm.nih.gov/pubmed?term=de%20Morais%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=12769713http://www.ncbi.nlm.nih.gov/pubmed?term=Xu%20JJ%5BAuthor%5D&cauthor=true&cauthor_uid=12769713http://www.ncbi.nlm.nih.gov/pubmed?term=Polzer%20RJ%5BAuthor%5D&cauthor=true&cauthor_uid=12769713http://www.ncbi.nlm.nih.gov/pubmed?term=Winter%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=12769713http://www.ncbi.nlm.nih.gov/pubmed/12769713
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
298
Liu, Y., 1999. Understanding the biological activity of amyloid proteins in vitro: from
inhibited cellular MTT reduction to altered cellular cholesterol homeostasis.
Prog Neuropsychopharmacol Biol Psychiatry 23: 377–395.
Lu, S., Guttendorf, R.J., Stewart, B.H., 1994. The mechanism of cefdinir transport in
CaCO-2 cells. Pharm Res 11: S-258.
Lu, T., Liang, Y., Song, J., Xie, L., Wang, G.J., Liu, X.D., 2006. J Pharm Biomed Anal
40: 1218–24.
Ma, J., Starck, S.R., Hecht, S.M., 1999. DNA polymerase b inhibitors from Tetracera
boiviniana. J Nat Prod 62: 1660–1663.
Ma, Y.C., Kim, H.Y., 1997. Determination of Steroids by Liquid Chromatography/Mass
Spectrometry. J Am Soc Mass Spectrorn 8: 1010-1020.
Macleod, K.F., Jacks, T., 1999. Insights into cancer from transgenic mouse models. J
Pathol 187: 43–60.
Makela, S.K., Eillis, G., 1988. Nonspecificity of a direct 17cx-hydroxyprogesterone
radioimmunoassay kit when used with samples from neonates. Clin Chern 34:
2070-2075.
Malgorzata, D.Z., Julita, K., Jolanta,, S., Teresa, W., Maciej, Z., Pawel, S., Marcin,
D., 2009. Esters of betulin and betulinic acid with amino acids have improved
water solubility and are selectively cytotoxic toward cancer cells, Bioorganic &
Medicinal Chemistry Letters 19: 4814–4817.
Mallet, C.R., Lu, Z., Mazzeo, J.R., 2004. A study of ion suppression effects in
electrospray ionization from mobile phase additives and solid-phase extracts.
Rap Commun Mass Spectromet 18: 49-58.
Martin, D.E., Blum, R., Doto, J., 2007. Multiple-dose pharmacokinetics and safety of
bevirimat, A novel inhibitor of HIV maturation, in healthy volunteers. Clin
Pharmacokinet 46(7): 589-98.
Martin, Y.C., Hansch, C., 1971. Influence of hydrophobic character on the relative rate of
oxidation of drugs by rat liver microsomes. J Med Chem 14: 777–779.
Masimirembwa, C.M., Breadburg, U., Andersson, T.B., 2003. Metabolic stability for drug
siacovery and development: pharmacokinetic and biochemical challenges. Clin
pharmacokinet 42(6): 515.
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
299
Matter, H., Baringhaus, K.H., Naumann, T., Klabunde, T., Pirard, B., 2001.
Computational approaches towards the rational design of drug-like compound
libraries. Comb Chem High Throughput Screen 4(6): 453-75.
Matuszewski, B., Constanzer, M.L., Chavez-Eng, C.M., 2003. Strategies for the
assessment of matrix effect in quantitative bioanalytical methods based on
HPLC-MS/MS. Analyt Chem 75: 3019-3030.
Meijer, D.K.F., 1989. Transport and metabolism in the hepatobiliary system. In:
Handbook of Physiology of the Gastrointestinal System, Vol. III, S.G., Schulz,
J.G., Forte, and B.B., Rauner, (eds). Oxford University Press, New York, 717-
758.
Meijer, D.K.F., Groothuis, G.M.M., 1991. Hepatic transport of drugs and proteins. In:
Oxford Textbook of Clinical Hepatology, Vol. 1, N., McIntyre, J., Benhama,
and H., Bircher, (eds). Oxford University Press, Oxford, 40-78.
Meijer, D.K.F., Mol, W.E.M., Muller, M., Kurz, G., 1990. Carrier mediated transport in
the hepatic distribution and elimination of drugs with special ref erences to the
category of organic cations. J Pharmaco Biopharm 18: 35-70.
Melzig, M.F., Bormann, H., 1998. Betulinic acid inhibits aminopeptidase N activity.
Planta Med 64: 655–657.
Mishra, G., Singh, M.K., Awasthi, A., Jaggi, M., Ahmad, F.J., 2011. LC-UV detection of
5-chloro-2,3-didehydroindolo[2’,3’:2,3] betulinic acid in rat plasma and its
application to a pharmacokinetic study. Chromatographia 73: 281-289. DOI
10.1007/s10337-010-1862-9.
Moser, A.R., Mattes, E.M., Dove, W.F., 1993. ApcMin, a mutation in the murine Apc
gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc
Natl Acad Sci 90: 8977–81.
Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55–63.
Mummaneni, V., Dressman, B., 1994. Intestinal uptake of cimetidine and ranitidine in
rat. Pharm Res 11: 1599.
Nagaraja, N.V., Paliwal, J.K., Gupta, R.C., 1999. Choosing the calibration model in assay
validation. J Pharm Biomed Anal 20: 433-438.
http://www.ncbi.nlm.nih.gov/pubmed?term=Matter%20H%5BAuthor%5D&cauthor=true&cauthor_uid=11562252http://www.ncbi.nlm.nih.gov/pubmed?term=Baringhaus%20KH%5BAuthor%5D&cauthor=true&cauthor_uid=11562252http://www.ncbi.nlm.nih.gov/pubmed?term=Naumann%20T%5BAuthor%5D&cauthor=true&cauthor_uid=11562252http://www.ncbi.nlm.nih.gov/pubmed?term=Klabunde%20T%5BAuthor%5D&cauthor=true&cauthor_uid=11562252http://www.ncbi.nlm.nih.gov/pubmed?term=Pirard%20B%5BAuthor%5D&cauthor=true&cauthor_uid=11562252http://www.ncbi.nlm.nih.gov/pubmed/11562252
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
300
Nassar, A.E., Talaat, R.E., Kamal, A.M., 2006. The impact of recent innovation in the use
of liqid chromatography –mass spectrometry in support of drug metabolism
studies: are we the way there yet? Curr Opin Drug Discov Devel 9(1): 61.
Nebert, D.W., Nelson, D.R., Coon, M.J., Estabrook, R.W., Feyereisen, R., Fujii-
Kuriyama, Y., Gonzales, F.J., Guengerich, F.P., Gunsalas, I.C., Johnson, E.F.,
Loper, J., Sato, R., Waterman, M.R., Waxman, D.J., 1991. The P450
superfamily-Update on new sequences, gene mapping and recommended
nomenclature. DNA Cell Biol 10: 1-14.
Nebert, D.W., Nelson, D.R., Coon, M.J., Estabrook, R.W., Feyereisen, R., Fujii-
Kuriyama, Y., Gonzales, F.J., Guengerich, F.P., Gunsalas, I.C., Johnson, E.F.,
Loper, J.C., Sato, R., Waterman, MR., Waxman, D.J., 1991. Correction. DNA
Cell Biol 10: 397-398.
Newman, D.J., Cragg, G.M,, Snader, K.M., 2003. Natural products as sources of new
drugs over the period 1981-2002. J Natur Prod 66: 1022-1037.
Newman, D.J., Cragg, G.M., Snader, K.M., 2000. The influence of natural products upon
drug discovery. Natur Prod Rep 17(3): 215-234.
Nishida, T., Gatmaitan, Z., Che, M., Arias, I.M., 1991. Rat liver canalicular membrane
vesicles contain an ATP-dependent bile acid transport system. Proc Natl Acad
Sci 88: 6590-6594.
Nishida, T., Gatmaitan, Z., Roy-Chowdhury, J., Arias, I.M., 1992a. Two distinct
mechanisms for bilirubin glucuronide transport by rat bile canalicular membrane
vesicles. Demonstration of defective ATP-dependent transport in rats with
inherited conjugated hyperbilirubinaemia. J Clin Invest 90: 2130-2135.
Nishida, T., Hardenbrook, C., Gatmaitan, Z., Arias, I.M., 1992b. ATP-dependent organic
anion transport in normal and TR- rat liver canalicular membranes. Am J Physiol
262: 629-G635.
Noda, Y., Kaiya, T., Kohda, K., Kawazoe,Y., 1997. Enhanced cytotoxicity of some
triterpenes toward leukemia L1210 cells cultured in lowpHmedia: Possibly a
newmode of cell killing. Chem Pharm Bull 45: 1665–1670.
Nomikos, T.V., Pater, J.L., Seymour, L., 2003. Clinical predictive value of the in vitro
cell line, human xenograft, and mouse allograft preclinical cancer models.
Clinical Cancer Research 9(11): 4227–4239.
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
301
O’Reilly, R.A., Welling, P.J., Wagner, J.G., 1971. Pharmakinetics of warfarin following
intravenous administration in man. Throm Diath Haemorrh 25: 178.
Ohgiya, S., Komori, M., Fujitani, T., Miura, T., Shinriki, N., Kamataki, T., 1989. Cloning
of human cytochome P-450 cDNA and its expression in Saccharomyces
cerevisiae. Biochem Int 18: 429-438.
Oude Elferink, R.P.J., Ottenhof, R., Radominska, A., Hofmann, A., Kuipers, F., and
Jansen, P.L.M., 1991. Inhibition of glutathione-conjugate secretion from
isolated hepatocytes by dipolar bile acids and other organic anions. Biochem J
274: 281-286.
Paget, S., 1889. Secondary growths of cancer of breast. Lancet 1:571–3.
Palm, K., Stenberg, P., Luthman, K., Artursson, P., 1997. Polar molecular surface
properties predict the intestinal absorption of drugs in humans. Pharma Res 14:
568-571.
Panchugnula, R., Thomas. N.S., 2000. Biopharmaceutics and pharmacokinetics in drug
research. Int J Pharm 201: 131-150.
Park, J.G., Kramer, B.S., Steinberg, S.M., Carmichael, J., Collins, J.M., Minna, J.D.,
Gazdar, A.F., 1987. Chemosensitivity testing of human colorectal carcinoma
cell lines using a tetrazolium-based colorimetric assay. Cancer Res 47: 5875-
5879.
Pedraglio, S., Rozio, M.G., Misiano P., Reali, V., Dondio, G., Bigogno, C., 2007. New
perspectives in bio- analytical techniques for preclinical characterization of drug
candidate: UPLC-MS/MS in vitro metabolism and pharmacokinetic studies. J
Pharm Biomed Anal 44 (3): 665.
Perucca, E, Richens, A., 1979. Reduction of oral bioavailability of lignocaine by
induction of first pass metablism in epileptic patients. Br J Pharmacol 7: 21.
Peterson, J.K., Houghton, P.J., 2004. Integrating pharmacology and in vivo cancer models
in preclinical and clinical drug development. Eur J Cancer 40: 837–44.
Phillips, R.M., Bibby, M.C., Double, J.A., 1990. A critical appraisal of the predictive
value of in vitro chemosensitivity assays. J Natl Cancer Inst 82: 1457–68.
Piasky, K.M., 1980. Disease induced changes in the plasma binding of basic drugs. Clin
Pharmacoin 5: 246.
Pidgeon, C., Ong, S., 1995. Predicting drug-membrane interactions. Chemtech 38-48.
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
302
Pinto, M., 1983. Enterocyte-like differentiation and polarization of the human colon
carcinoma cell line Caco-2 in culture. Biol Cell 47: 323-330.
Piquette, M.M., Jamali, F., 1977. Pharmacokinetics and multiple peaking of acebutolol
enantiomers in rats. Biopharm Drug Dispos 18: 543.
Pisha, E., Chai, H., Lee, I.S., Chagwedera, T.E., Farnsworth, N.R., Cordell, A.C.,
Beecher, C.W.W., Fong, H.H.S., Kinghorn, A.D., Brown, D.M., Wani, M.C.,
Wall, M.E., Hieken, T.J., Das, Gupta, T.K., Pezzuto, J.M., 1995. Discovery of
betulinic acid as a selective inhibitor of human melanoma that functions by
induction of apoptosis. Nat Med 1: 1046–1051.
Plowman, J., 1997. Human tumour xenograft models in NCI drug development. In:
Teicher B, editor. Anticancer drug development guide: preclinical screening,
clinical trials, and approval: Humana Press Inc. 101–25.
Plowman, J., Camalier, R., Alley, M., Sausville, E., Schepartz, S., 1999. US-NCI testing
procedures. In: Fiebig HH, Burger AM, editors. Relevance of tumour models for
anticancer drug development. Contrib Oncol 54: 121–35.
Poggesi, L., 2004. Predicting human pharmacokinetics from preclinical data. Curr Opin
Drug Discov Devel 7(1): 100.
Pokrovskii, A.G., Shintyapina A.B., Pronkina N.V., Kozhevnikov V.S., Plyasunova
O.A., Shul’ts E.E., Tolstikov G.A., 2006. Activation of Apoptosis by
Derivatives of Betulinic Acid in Human Tumor Cells in vitro, Doklady
Biochemistry and Biophysics 407: 94–97.
Pond, S.M., Tozer, T.M., 1984. First pass elimination, basic concepts and clinical
consequences. Clin Pharmacokin 9: 1.
Powell, J.R., Vozeh. S., Hopewell, P., Costello, J., Sheiner, L.B., Reigelman, S., 1975.
Theophyline disposition in accurately ill hospitalized patients. Am Rev Respir
Dis 11: 229.
Prakash, C., Shaffer, C.L., Nedderman, A., 2007. Analytical strategies for identifying
drug metabolites. Mass spectrum Rev 26(3):340.
Prentis, R.A., Lis, Y., Walker, S.R., 1988. Pharmaceutical innovation by the seven UK-
owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 25(3):
387–396.
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=PubMed&term=%20Prentis%2BRA%5bauth%5dhttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=PubMed&term=%20Lis%2BY%5bauth%5dhttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=PubMed&term=%20Walker%2BSR%5bauth%5d
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
303
Purdie, C.A., Harrison, D.J., Peter, A., 1994. Tumour incidence, spectrum and ploidy in
mice with a large deletion in the p53 gene. Oncogene 9: 603–9.
Qiu, L., Wang, Q., Di, W., Jiang, Q., Schefeller, E., Derby, S., Wanebo, H., Yan, B.,
Wan, Y., 2005. Transient activation of EGFR/AKT cell survival pathway and
expression of survivin contribute to reduced sensitivity of human melanoma
cells to betulinic acid. Int J Oncol 27(3): 823-30.
Qiuling, W.U., Jing, H.E., Jun, F.A.N.G., Mei, 2010. Antitumor Effect of Betulinic
Acid on Human Acute Leukemia K562 Cells in vitro, J Huazhong Univ Sci
Technol Med Sci 30(4): 453-457.
Reinoso, R.F., Farran, R., Moragon, T., Gracia-Soret, A., Martinez, L., 2001.
Pharamcokinetics of E-6087, anew anti-inflammatory agent, in rats and dogs.
Biopharm Drug Dispos 22: 231.
Rieber, M., Rieber, M.S., 1998. Induction of p53 without increase in p21WAF1 in
betulinic acid-mediated cell death is preferential for human metastatic
melanoma. DNA Cell Biol 17: 399–406.
Rieber, M., Rieber, M.S., 2006. Signalling responses linked to betulinic acid-induced
apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid
melanoma irrespective of p53 status. Int J Cancer 118: 1135-1143.
Rinaki, E., Valsami, G., Macheras, P., 2003. Quantitative Biopharmacuetics
Classification System; the central role of dose/solubility ratio. Pharm Res 20:
1917.
Roberts, S.A., 2001. High-throughput screening approaches for investigating drug
metabolism and pharmacokinetics. Xenobiotica 31(8-9): 557-89.
Roberts, S.A., 2003. Drug metabolism and pharmacokinetics in drug discovery. Curr
Opin Drug Discov Devel 6(1): 66-80.
Rodrigues, A.D., 1997. Preclinical drug metabolisim in the age of high–throughput
screening: an industrial perspective. Pharm Res 14: 1504- 1510.
Rose, J., Holbech, H., Lindholst, C., Nortum, U., Povlsen, A., Korsgaard, B., 2002.
Bjerrregaard CPo Vitellogenin induction by 17/3-estradiol and l Zo-
ethinylestradiol in male zebrafish (Danio rerio) Biochem Physio C 131: 531-
537.
http://www.ncbi.nlm.nih.gov/pubmed?term=Roberts%20SA%5BAuthor%5D&cauthor=true&cauthor_uid=11569526http://www.ncbi.nlm.nih.gov/pubmed/11569526http://www.ncbi.nlm.nih.gov/pubmed?term=Roberts%20SA%5BAuthor%5D&cauthor=true&cauthor_uid=12613278http://www.ncbi.nlm.nih.gov/pubmed/12613278http://www.ncbi.nlm.nih.gov/pubmed/12613278
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
304
Rothen-Rutishauser, B., Kraemer, S.D., Braun, A., Guenthert, M., Wunderli-Allenspach,
H., 1998. MDCK cell cultures as an epithelial in vitro model: cytoskeleton and
tight junctions as indicators for the definition of age-related stages by confocal
microscopy. Pharm Res 15: 964-971.
Rowland, M., 1972. Influence of route of administration on drug availability. J Pharm
Sci 1: 70.
Rubenstein, K., 2003. Advancein lead optimization accelerating drug discovery and
development. Report# 27, Cambridge healthcare Institute.
Rubinstein, L.V., Shoemaker, R.H., Paull, K.D., Simon, R.M., Tosini, S., Skehan, P.,
Scudiero, D., Monks, A., Boyd, M.R., 1990 Comparison of in vitro anticancer
drug screening datagenerated with a tetrazolium assay versus a protein assay
against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-
1118.
Rusmawati, W.M.W., Ahmad, F.B.H., Anuar, K., Hamdan, S., 2001. Solubility of
betulinic acid in the microemulsion system of methyl acetate/Tween 80:
BRIJ30/H2O. Oriental J Chem 16: 393–398.
Sabarinath, S., Madhusudanan, K.P., Gupta, R.C., 2005. Pharmacokinetics of the
diastereomers of arteether, a potent antimalarial drug, in rats. Biopharm Drug
Dispos. 26: 211.
Sakaguchi, E., 1990. Digesta retention and fibre digestion in brushtail possums, ringtail
pos sums and rabbits. Comparative Biochemistry and Physiology 96A: 351.
Salti, G.I., Kichina, J.V., Das, Gupta, T.K., Uddin, S., Bratescu, L., Pezzuto, J.M., Mehta,
R.G., Constantinou, A.I., 2001. Betulinic acid reduces ultraviolet-C-induced
DNA breakage in congenital melanocyte naeval cells: Evidence for a potential
role as a chemopreventive agent. Melanoma Res 11: 99–104.
Sandberg, F., Dutschewska, H., Christov, V., Spassov, S., 1987. Spondianthus preussii
var. glaber Engler: Pharmacological screening and occurrence of triterpenes.
Acta Pharm Suec 24: 253–256.
Sanjivanjit, B., Karim, K., Ian, P., Greg, P., 2007. Mol. Pharmaceutics 4 (4): 556–560.
Sargent, J.M., 2003. The use of the MTT assay to study drug resistance in fresh tumour
samples. Recent Results Cancer Res 161:13-25.
http://pubs.acs.org/action/doSearch?action=search&author=Bhal%2C+Sanjivanjit+K.&qsSearchArea=authorhttp://pubs.acs.org/action/doSearch?action=search&author=Kassam%2C+Karim&qsSearchArea=authorhttp://pubs.acs.org/action/doSearch?action=search&author=Peirson%2C+Ian+G.&qsSearchArea=authorhttp://pubs.acs.org/action/doSearch?action=search&author=Pearl%2C+Greg+M.&qsSearchArea=authorhttp://www.ncbi.nlm.nih.gov/pubmed?term=Sargent%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=12528795http://www.ncbi.nlm.nih.gov/pubmed/12528795
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
305
Schmidt, D., Lynch, J., 2003. Evaluation of the reproducibility of Parallel Artificial
Membrane Permeability Assay (PAMPA). Millipore corporation application
note, Literature Notes AN1728EN00.
Schmidt, M.L., Kuzmanoff, K.L., Ling-Indeck, L., Pezzuto, J.M., 1997. Betulinic acid
induces apoptosis in human neuroblastoma cell lines. Eur J Cancer 33: 2007–
2010.
Schoene, C., Nedderman, A.N.R., Houghton, E., 1994. Preliminary study of the
metabolism of 17cx-methyltestosterone in horses utilizing gas chromatography-
mass spectrometric techniques. Analyst 119: 2537.
Seifert, M., Brenne-weib, G., Haindl, S., Nusser, M., Obst, U., Hock, B., 1999.
Frensenius. A new concept for the bioeffects-related analysis of xenoestrogens:
Hyphenation of receptor assays with LC-MS. J Anal Chern 363: 767.
Selby, P., Buick, R.N., Tannock I., 1983. A critical appraisal of the human tumor stem
cell assay. New England Journal of Medicine 308: 129-134.
Selick, H.E., Beresford, A.P., Tarbit, M.H., 2002.The emerging importance of predictive
ADME simulation in drug discovery. Drug Discov Today 7(2):109-16.
Selzer, E., Pimentel, E., Wacheck, V., Schlegel, W., Pehamberger, H., Jansen, B.,
Kodym, R., 2000. Effects of betulinic acid alone and in combination with
irradiation in human melanoma cells. J Invest Dermatol 114: 935– 940.
Seydel, J.K., Miller, G., Doukas, P.H. 1973. Structure-activity correlations of
sulfonamides in cell-free systems compared to correlations obtained in whole
cell systems and in vivo. in Medicinal Chemistry, ed Pratesi, P., (Butterworths,
London, UK), 139–151.
Seydel, J.K., Schaper, K.J., 1986. Quantitative structure-pharmacokinetic relationships
and drug design. in Pharmacokinetics: Theory and Methodology, eds Rowland,
M., Tucker, G., (Pergamon Press, New York), 311–366.
Shackleton, C.H.L., 1986. Profiling steroid hormones and urinary steroids. J Chromatogr
B. Biomed Appl 379: 91-156.
Shackleton, C.H.L., 1993.Mass spectrometry in the diagnosis of steroid-related disorders
and in hypertension research. J Steroid Biochem Molec Biol 45: 127-140.
Shah, V.P., Midha, K.K., Dighe, S., McGilveray, I.I., Skelly, J.P., Yacobi, A., Layloff,
T., Viswanathan, C.T., Cook, C.E., McDowall, R.D., Pittman, K.A., Spector, S.,
1992. Analytical methods validation: bioavailability, bioequivalence and
http://www.ncbi.nlm.nih.gov/pubmed?term=Selick%20HE%5BAuthor%5D&cauthor=true&cauthor_uid=11790621http://www.ncbi.nlm.nih.gov/pubmed?term=Beresford%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=11790621http://www.ncbi.nlm.nih.gov/pubmed?term=Tarbit%20MH%5BAuthor%5D&cauthor=true&cauthor_uid=11790621http://www.ncbi.nlm.nih.gov/pubmed/11790621
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
306
pharmacokinetic studies. Conference report. Pharm Res 9: 588-592.
Shah, V.P., Midha, K.K., Findlay, J.W., Hill, H.M., Hulse, J.D., McGilveray, I.I.,
McKay, G., Miller, K.J., Patnaik, R.N., Powell, M.L., Tonelli, A.,
Viswanathan, C.T., Yacobi, A., 2000. Bioanalytical method validation--a
revisit with a decade of progress. Pharm Res 17: 1551-1557.
Shand, D.G., Rangro, R.E., Evans, G.H., 1972. The disposition of propranolol. IL
Hepatic elimination in the rat. Pharmacol 8: 344.
Shargel, L., Yu, A.B.C., 1985. Applied pharmacokinetics and Biopharmaceutics, 2nd
edition. Appleton-Century Crafts, Norwalk, CT. 197.
Shargel, L., Yu, A.B.C., 1993. Applied Biopharmaceutics and Pharmacokinetics.
Appleton & Lange: Norwalk, Connecticut.
Sharma, A., Jusko W.J., 1998. Characteristics of indirect pharmacodynamic models and
application to clinical drug responses. Br J Clin Pharmacol 45: 229-239.
Shin, Y.G., Cho, K.H., Chung, S.M., Graham, J., Gupta, T.K.D., Pezzuto, J.M., 1999.
Determination of betulinic acid in mouse blood, tumor, and tissue homogenates
by liquid chromatography–electrospray mass spectrometry. J Chromatogr B
732: 331–336.
Singh, S.K., Mehrotra, N., Sabarinath, S., Gupta, R.C., 2003. HPLC-UV method
development and validation for 16-dehydropregnenolone, a novel oral
hypolipidaemic agent, in rat biological matrices for application to
phannacokinetic studies. J Pharm Biomed Anal 33: 755-764.
Singh, S.S., 2006 Preclinical pharmacokinetics: an approach towards safer and efficacious
drugs. Curr Drug Metab 7(2): 165-82.
Singh, S.S., Patro, B., Tripathi, V., Srivastava, A., Pandey, S.C., Ghosh, A.C., 2002.
Betulinic acid and its pharmacological activity-a review. J Med Aromatic Plant
Sci 24: 1031-1037.
Sippel, J., Suchy, F.J., Ananthanarayanan, M., Perlmutter, D.H., 1993. The rat liver
ectoATPase is also a canalicular bile acid transport protein. J Biol Chem 268:
2083-2091.
Smith, D.A., Obach, R.S., 2005. Drug Metab Dispos 33: 1409–1417.
Smith, R.L., 1973. The Excretory Function of Bile. The Elimination of Drugs and Toxic
Substances in Bile. Chapman and Hall, London.
http://www.ncbi.nlm.nih.gov/pubmed?term=Singh%20SS%5BAuthor%5D&cauthor=true&cauthor_uid=16472106http://www.ncbi.nlm.nih.gov/pubmed/16472106
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
307
Son, L.B., Kaplun, A.P., Symon, A.V., Shpilevsky, A.A., Grigoriev, V.B., Shvets, V.I.,
1998. Solubilization of betulinic acid, a new antimelanoma compound. Proceed
Int Symp Control Rel Bioact Mater 25: 419–420.
Sorokina, I.V., Tolstikova, T.G., Zhukova, N.A., Petrenko, N.I., Uzenkova, N.V.,
Shul’ts, E.E., Popova, N.A., 2006. Antitumor and Antimetastatic Effects of
Betulonic Acid Amides in Mice with Transplantable Lewis Carcinoma,
Bulletin of Experimental Biology and Medicine 142(1): 78-81.
Steele, J.C., Warhurst, D.C., Kirby, G.C., Simmonds, M.S., 1999. In vitro and in vivo
evaluation of betulinic acid as an antimalarial. Phytother Res 13: 115-119.
Stewart, B.H., Chan, O.H., Lu, R.H., Reyner, E.L., Schmid, H.L., Hamilton, H.W.,
Steinbaugh, B.A., Taylor, M.D., 1995. Comparison of intestinal permeabilities
determined in multiple in vitro and in situ models: relationship to absorption in
humans. Pharm Res 12: 693-699.
Stewart, B.W., Kleihues, P., 2003. ―WORLD CANCER REPORT‖ and Published by
International Agency for Research on Cancer, World Health Organization 12-
20.
Stewart, T.A., Pattengale, P.K., Leder, P., 1984. Spontaneous mammary adenocarcinomas
in transgenic mice that carry and express MTV/myc fusion genes. Cell 38: 627–
37.
Stoner, C.L., Gifford, E., Stankovic, C., Lepsy, C.S., Brodfuehrer, J., Prasad, J.V.,
Surendran, N., 2004. Implementation of an ADME enabling selection and
visualization tool for drug discovery. J Pharm Sci 93(5): 1131-41.
Subramanian, G., Mjalli, A.M., Kutz, M.E., 2006. Integrated approaches to perform in
silico drug discovery. Curr Drug Discov Technol 3(3): 189-97.
Sugawara, M., 2005. The use of an in vitro dissolution and absorption system to evaluate
oral absorption of two weak bases in pH-independent controlledrelease
formulations. Eur J Pharm Sci 26: 1–8.
Suggitt, M., Swaine, D.J., Pettit, G.R., Bibby, M.C., 2004. Characterisation of the hollow
fibre assay for the determination of microtubule disruption in vivo. Clin Cancer
Res 10: 6677–85.
http://www.ncbi.nlm.nih.gov/pubmed?term=Stoner%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Gifford%20E%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Stankovic%20C%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Lepsy%20CS%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Brodfuehrer%20J%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Prasad%20JV%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Surendran%20N%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed/15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Subramanian%20G%5BAuthor%5D&cauthor=true&cauthor_uid=17311564http://www.ncbi.nlm.nih.gov/pubmed?term=Mjalli%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=17311564http://www.ncbi.nlm.nih.gov/pubmed?term=Kutz%20ME%5BAuthor%5D&cauthor=true&cauthor_uid=17311564http://www.ncbi.nlm.nih.gov/pubmed/17311564
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
308
Sun, D., Yu, L.X., Hussain, M.A., Wall, D.A., Smith, R.L., Amidon, G.L., 2004 . In vitro
testing of drug absorption for drug developability assessment: forming an
interface between in vitro preclinical data and clinical outcome. Curr Opin Drug
Discov Devel 7(1): 75.
Suto, A., Kubota, T., Shimoyama, Y., Ishibiki, K., Abe, O., 1989. MTT assay with
reference to the clinical effect of chemotherapy. J Surg Oncol 42: 28-32.
Symon, A.V., Veselova, N.N., Kaplun, A.P., Vlasenkova, N.K., Fedorova, G.A.,
Lyutik, A.I., Gerasimov, G.K., Shvets, V.I., 2005. Synthesis and Antitumor
Activity of Cyclopropane Derivatives of Betulinic and Betulonic Acids,
Russian Journal of Bioorganic Chemistry 31(3): 286–291.
Syrovets, T., Buchele, B., Gedig, E., Slupsky, J.R., Simmet, T., 2000. Acetyl-boswellic
acids are novel catalytic inhibitors of human topoisomerase I and IIa. Mol
Pharm 58: 71–81.
Tarbit, M.H., Berman, J., 1998. High throughput approach for evaluating absorption,
distribution, metabolism and excretion properties of lead compounds. Cur Opin
Chem Biol 2: 411-416.
Tassaneeyakul, W., Birkett, D.J., Veronese, M.E., McManus, M.E., Tukey, R.H.,
Quattrochi, L.C., Gelboin, H.V., Miners, J.O., 1993. Specificity of substrate and
inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp
Ther 265(1): 401-7.
Thomas, O., Greg, K., MultiScreen® Solubility Filter Plate. Quantitative method to
determine drug aqueous solubility: optimization and correlation to standard
method.
Thompson, T.N., 2000. Early ADME in support of drug discovery : the role of metabolic
stability studies . Curr Drug Metab 1(3): 215.
Toon, S., Rowland, M., 1983. Structure-pharmacokinetic relationships among the
barbiturates in the rat. J Pharmacol Exp Ther 225: 752–763.
Twentyman, P.R., Fox, N.E., Rees, J.K.H., 1989. Chemosensitivity testing of fresh
leukaemia cells using the MTT colorimetric assay. Br J Haematol 71: 19-24.
-
Ph.D Thesis Estimation of New Anticancer…(Bibliography)
309
U.S. Environmental Protection Agency, 1997. Health Effects Test Guidelines OPPTS
870.7485 Metabolismand Pharmacokinetics.
www.epa.gov/epahome/research.htm
U.S. FDA, Guidance for Industry. Estimating the maximum safe starting dose in initial
clinical trials for therapeutics in adult healthy volunteers. 2005.
www.fda.gov/cder/guidance
U.S. FDA., 1997. Guidance for Industry. Drug metabolism/drug interaction studies in the
drug development process: studies in vitro. www.fda.gov/cder/guidance
U.S. FDA., 2002. Guideline for Metabolism Studies and for Selection of Residues for
Toxicological Testing. www.fda.gov/cvm/guidance/guideline3pt1.html
U.S. FDA., 2005. Guidance for Industry. Safety Testing of Drug Metabolites.
www.fda.gov/cder/guidance
Udeani, G.O., Zhao, G.M., Shin, Y.G., Cooke, B.P., Graham, J., Beecher, C.W.W.,
Kinghorn, A.D., Pezzuto, J.M., 1999. Pharmacokinetics and tissue distribution
of betulinic acid in CD-1 mice. Biopharm Drug Dispos 20: 379–383.
Ungell, A.B., 2004. Caco-2 replace or refine?. Drug Discov Today Technol 1(4): 423-430.
Ungell, A-L. 1997. In vitro absorption studies and their relevance to absorption from the
GI tract. Drug Dev Industr Pharm 23: 879-892.
Unger, S.E., 1999. Using mass spectrometry to determine ADME properties III drug
discovery. Annu Rep Med Chern 34: 307-316.
Urban, M., Sarek, J., Klinot, J., Korinkova, G., Hajduch, M., 2004. Synthesis of A-seco
derivatives of betulinic acid with cytotoxic activity. J Nat Prod 67: 1100-1105.
Valner, J.J., 1977. Binding of drugs with albumin and plasma proteins. J Pharm Sci 66:
447.
Van, W.H., 2002. High-throughput and in silico techniques in drug metabolism and
pharmacokinetics, Curr Opin Drug Discov Devel 5(1): 33-43.
Van, W.H., 2005. From in vivo to in vitro/in silico ADME: progress and challenges.
Expert Opin Drug Metab Toxicol 1(1):1-4.
Van, W.H., Gifford, E., 2003. ADMET in silico modelling: towards prediction paradise?
Nat Rev Drug Discov 2(3):192-204.
Van-Hoof, N., Courtheyn, D., Philippe-Antignac, J., Van-De-Wiele, M., Poelmans, S.,
Noppe, H., Brabander, D., 2005. Multi-residue liquid chromatography/tandem
http://www.epa.gov/epahome/research.htmhttp://www.fda.gov/cder/guidancehttp://www.fda.gov/cder/guidancehttp://www.ncbi.nlm.nih.gov/pubmed?term=van%20de%20Waterbeemd%20H%5BAuthor%5D&cauthor=true&cauthor_uid=11865671http://www.ncbi.nlm.nih.gov/pubmed/11865671http://www.ncbi.nlm.nih.gov/pubmed/16922647http://www.ncbi.nlm.nih.gov/pubmed?term=van%20de%20Waterbeemd%20H%5BAuthor%5D&cauthor=true&cauthor_uid=12612645http://www.ncbi.nlm.nih.gov/pubmed?term=Gifford%20E%5BAuthor%5D&cauthor=true&cauthor_uid=12612645htt